Abbott Laboratories (ABT) recently experienced a stock sell-off following its earnings report, driven by lowered EPS guidance and weakness in its Nutrition segment. Despite this, the company offers a 2.5% dividend yield with over 50 years of dividend increases and trades at a forward P/E below its 5-year average, making it attractive for long-term investors. Abbott's strong balance sheet includes $8.5 billion in cash and manageable debt, with free cash flow expected to grow by 40.5% by 2028. The EPS guidance cut is partly due to dilution from the Exact Sciences acquisition, but growth is projected to reaccelerate after 2026, supporting a potential 41% upside from current levels.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by rising demand for rapid diagnostics, AI integration, and precision veterinary medicine, alongside i...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by increasing demand for rapid diagnostics, AI integration, robotic workflows, and a focus on companio...
